Abstract 1562P
Background
Zolbetuximab showed efficacy for gastric cancer with Claudin (CLDN)18.2 expression. CLDN18.2 is reported to be expressed in about 20-50% of gastric cancer, but the definitions varied in previous reports and the relationship with prognosis is controversial. The present study aimed to examine the expression of CLDN18.2 based on SPOTLIGHT/GLOW study and the relationship with prognosis and clinical/molecular characteristics in resected gastric cancer.
Methods
We used a tissue microarray set including gastric cancer samples resected in our institution between July 1989 and September 2009. VENTANA CLDN18 (43-14A) assay was used for immunohistochemistry (IHC) of CLDN18.2. CLDN18.2 expression was judged as positive when ≥75% of the tumor cell membrane was stained in moderate-to-strong intensity by IHC. The Combined Positive Score (CPS) was evaluated using Dako PD-L1 28-8 pharmDx assay.
Results
CLDN18.2 was evaluable in 366 samples and expressed in 139 samples (38%). Clinical data was available in 129 patients (pts) with CLDN18.2+ vs 191 CLDN18.2- pts. Patient characteristics in the CLDN18.2+ group vs the CLDN18.2- group were as follows; median age (range), 64 (27 - 85) vs 66 (35 - 83); gender male 94 (73%) vs 139 (73%); HER2 positive 11 (10%) vs 19 (10%); CPS ≥5, 64 (50%) vs 88 (46%); dMMR, 4 (3.1%) vs 5 (2.6%); Lauren classification diffuse, 71 (55%) vs 107 (56%); pTstage 1/2/3/4, 13/15/17/84 vs 17/34/28/112; pNstage 0/1/2/3, 27/31/32/39 vs 41/39/50/61; pStage I/II/III, 13/36/80 vs 14/68/109; and adjuvant S-1, 43 (33%) vs 54 (28%). Three-year RFS was 56.8% in the CLDN18.2+ group vs 60.3% in the CLDN18.2- group (HR = 1.07 [95% CI 0.77-1.49], p = 0.68). Three-year OS was 66.9% in the CLDN18.2+ group vs 68.7% in the CLDN18.2- group (HR = 1.13 [95% CI 0.80-1.59], p = 0.49).
Conclusions
CLDN18.2 expression was observed in 38% of resected gastric cancer samples, which was consistent with previous reports. CLDN18.2 expression was not related to prognosis and specific relationship was not observed in clinical/molecular characteristics of resected gastric cancer.
Clinical trial identification
Editorial acknowledgement
The Authors would like to thank Charles McKay for English language editing.
Legal entity responsible for the study
M. Furuta.
Funding
Has not received any funding.
Disclosure
M. Furuta: Financial Interests, Personal, Invited Speaker: Eli Lilly, Bristol Myers Squibb, Merck & Co., Inc., Ono Pharamceutical Co. Ltd., , Takeda Pharmaceutical Company Limited. N. Machida: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Ono, Taiho, MSD, Daiichi Sankyo, Yakult, Eli Lilly Japan, Chugai, Astellas, Takeda, Merck biopharma, Nichi-Iko, Nippon-Kayaku; Financial Interests, Institutional, Local PI: Bristol Myers Squibb, Ono, Daiichi Sankyo, Astellas, MSD, Amgen, ALX Oncology, Seagen. J. Furuse: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical, Bayer, Eisai, Eli Lilly Japan, MSD, Yakult Honsha, Chugai Pharma, Novartis Pharma, AstraZeneca, Pfizer, Takeda, Taiho Pharmaceutical, Sanofi, Mylan EPD, EA Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Teijin pharma, Servier Japan, Incyte; Financial Interests, Personal, Advisory Board: Fuji film, Mudi Pharma, Onco Therapy Science, Merck Bio, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Chugai Pharma, Astellas, AstraZeneca, Takara bio, Delta-Fly-Pharma, Incyte Japan; Financial Interests, Institutional, Research Grant: Ono Pharmaceutical, MSD, Merck Bio, J-Pharma, Taiho Pharmaceutical, Takeda, Chugai Pharma, AstraZeneca, Yakult Honsha, Eisai, Daiichi Sankyo, Mochida, Sanofi, Sumitomo Dainippon Bayer, Astellas, Incyte Japan; Financial Interests, Personal, Steering Committee Member: Merck Bio, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Astellas, AstraZeneca, Incyte Japan. All other authors have declared no conflicts of interest.
Resources from the same session
1478P - Circulating pre-treatment T-Cell receptor repertoire as a predictive biomarker in non-small cell lung cancer patients treated with pembrolizumab
Presenter: Elin Gray
Session: Poster session 21
1479P - Association between high baseline low density neutrophils and resistance to immunotherapy in untreated non-small cell lung cancer: Molecular characterization of low-density neutrophils
Presenter: Hugo Arasanz
Session: Poster session 21
1480P - Integrating the on-treatment mGPS improves prognostic accuracy of imaging-based staging in patients with non-small-cell lung cancer (NSCLC) treated with immune-checkpoint inhibitors
Presenter: Jonas Saal
Session: Poster session 21
1481P - Singular immune-related adverse events and efficacy outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Jose Miguel Jurado García
Session: Poster session 21
1482P - Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in elderly adults aged over 75 years
Presenter: Jun Sakakibara-Konishi
Session: Poster session 21
1483P - Challenge of systemic first-line treatment of elderly lung cancer patients
Presenter: Konstantinos Ferentinos
Session: Poster session 21
1484P - Impact of concomitant KRAS/STK11 or KRAS/KEAP1 mutations on response to immune checkpoint inhibition in NSCLC: A real-world data analysis
Presenter: Louisa Hempel
Session: Poster session 21
1485P - Systemic inflammatory index dynamics at 6 weeks as an early surrogate for clinical benefit in patients with NSCLC and PD-L1≥50% expression treated with pembrolizumab: Data from the real-life practice
Presenter: Magdalena Knetki-Wroblewska
Session: Poster session 21
1486P - Treatment patterns and real-world clinical outcomes of metastatic non-small cell lung cancer patients in the immunotherapy era
Presenter: Sarah Sharman Moser
Session: Poster session 21
1487P - Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated results
Presenter: Qi-Ming Wang
Session: Poster session 21